COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey
Standard
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. / Ljungman, Per; de la Camara, Rafael; Mikulska, Malgorzata; Tridello, Gloria; Aguado, Beatriz; Zahrani, Mohsen Al; Apperley, Jane; Berceanu, Ana; Bofarull, Rodrigo Martino; Calbacho, Maria; Ciceri, Fabio; Lopez-Corral, Lucia; Crippa, Claudia; Fox, Maria Laura; Grassi, Anna; Jimenez, Maria-Jose; Demir, Safiye Koçulu; Kwon, Mi; Llamas, Carlos Vallejo; Lorenzo, José Luis López; Mielke, Stephan; Orchard, Kim; Porras, Rocio Parody; Vallisa, Daniele; Xhaard, Alienor; Knelange, Nina Simone; Cedillo, Angel; Kröger, Nicolaus; Piñana, José Luis; Styczynski, Jan.
in: LEUKEMIA, Jahrgang 35, Nr. 10, 10.2021, S. 2885-2894.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey
AU - Ljungman, Per
AU - de la Camara, Rafael
AU - Mikulska, Malgorzata
AU - Tridello, Gloria
AU - Aguado, Beatriz
AU - Zahrani, Mohsen Al
AU - Apperley, Jane
AU - Berceanu, Ana
AU - Bofarull, Rodrigo Martino
AU - Calbacho, Maria
AU - Ciceri, Fabio
AU - Lopez-Corral, Lucia
AU - Crippa, Claudia
AU - Fox, Maria Laura
AU - Grassi, Anna
AU - Jimenez, Maria-Jose
AU - Demir, Safiye Koçulu
AU - Kwon, Mi
AU - Llamas, Carlos Vallejo
AU - Lorenzo, José Luis López
AU - Mielke, Stephan
AU - Orchard, Kim
AU - Porras, Rocio Parody
AU - Vallisa, Daniele
AU - Xhaard, Alienor
AU - Knelange, Nina Simone
AU - Cedillo, Angel
AU - Kröger, Nicolaus
AU - Piñana, José Luis
AU - Styczynski, Jan
N1 - © 2021. The Author(s).
PY - 2021/10
Y1 - 2021/10
N2 - This study reports on 382 COVID-19 patients having undergone allogeneic (n = 236) or autologous (n = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). The median age was 54.1 years (1.0-80.3) for allogeneic, and 60.6 years (7.7-81.6) for autologous HCT patients. The median time from HCT to COVID-19 was 15.8 months (0.2-292.7) in allogeneic and 24.6 months (-0.9 to 350.3) in autologous recipients. 83.5% developed lower respiratory tract disease and 22.5% were admitted to an ICU. Overall survival at 6 weeks from diagnosis was 77.9% and 72.1% in allogeneic and autologous recipients, respectively. Children had a survival of 93.4%. In multivariate analysis, older age (p = 0.02), need for ICU (p < 0.0001) and moderate/high immunodeficiency index (p = 0.04) increased the risk while better performance status (p = 0.001) decreased the risk for mortality. Other factors such as underlying diagnosis, time from HCT, GVHD, or ongoing immunosuppression did not significantly impact overall survival. We conclude that HCT patients are at high risk of developing LRTD, require admission to ICU, and have increased mortality in COVID-19.
AB - This study reports on 382 COVID-19 patients having undergone allogeneic (n = 236) or autologous (n = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). The median age was 54.1 years (1.0-80.3) for allogeneic, and 60.6 years (7.7-81.6) for autologous HCT patients. The median time from HCT to COVID-19 was 15.8 months (0.2-292.7) in allogeneic and 24.6 months (-0.9 to 350.3) in autologous recipients. 83.5% developed lower respiratory tract disease and 22.5% were admitted to an ICU. Overall survival at 6 weeks from diagnosis was 77.9% and 72.1% in allogeneic and autologous recipients, respectively. Children had a survival of 93.4%. In multivariate analysis, older age (p = 0.02), need for ICU (p < 0.0001) and moderate/high immunodeficiency index (p = 0.04) increased the risk while better performance status (p = 0.001) decreased the risk for mortality. Other factors such as underlying diagnosis, time from HCT, GVHD, or ongoing immunosuppression did not significantly impact overall survival. We conclude that HCT patients are at high risk of developing LRTD, require admission to ICU, and have increased mortality in COVID-19.
U2 - 10.1038/s41375-021-01302-5
DO - 10.1038/s41375-021-01302-5
M3 - SCORING: Journal article
C2 - 34079042
VL - 35
SP - 2885
EP - 2894
JO - LEUKEMIA
JF - LEUKEMIA
SN - 0887-6924
IS - 10
ER -